Aim: to assess clinical safety and postoperative audiological outcomes in Spanish speaking patients that underwent surgery with Nurotron™ cochlear implant.Method: A Before-and-after study was performed.Patients with bilateral severe to profound neurosensorial hearing loss or patients with unilateral deafness with/without tinnitus were included in the study.Repeated-measures within-subjects for assess pure tone thresholds and speech performance (Bilingual Test) with a detailed monitoring to establish security or adverse effects were performed.T-test for paired samples was used for statistical analysis.Results: 32 patients were included, 18 (56.3%)men and 14 (43.7%)women.Mean age at the time of surgery was 49.1±19.8years.30 (93.8%) patients were postlingual and 2 (6.2%) were prelingual.In 17 (53.1%)patients the hearing loss was unilateral, and in 15 (46.9%) the hearing loss was bilateral.The mean follow-up of the group was 22.2±9.0months(minimum=5months and maximum=40months).As major complication only one patient (3.1%) with high-spending gusher was reported, related with ossified cochlea and unrelated with the brand of the cochlear implant.Hard failures and extrusions are not reported in the followed-up period in this group.The average of inserted electrodes was 21.9 (the patient with ossified cochlea has 6 working electrodes), and 31 patients are using the cochlear implant more than twelve hours/day (one patient died of omentum cancer).In the postlingual patients, the mean pure tone average in free field audiometry was 33.2dB at six months (n=28, p<0.05 respect preoperative), the speech discrimination score at 65db SPL was over 50% at six months (n=26, p<0.05 respect to preoperative), and over 70% at 12 months (n=25, p<0.05 respect to preoperative).A statistically significant reduction was observed in patients with tinnitus (p <0.05).All patients are using the Venus processor with the APS strategy. Conclusion:The clinical safety and audiological outcomes are satisfactory and supports the reliable use of the Nurotron™ cochlear implant; we need more studies focused in long term follow-up and quality of life outcomes to confirm these results.